Clinical overview of irbesartan: Expanding the therapeutic window in hypertension

Journal of Hypertension, Supplement

Volumn 15, Issue 7, 1997, Pages

  Man In't Veld, Arie J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin II receptor antagonists; Hypertension; Irbesartan; Therapeutic window

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FELODIPINE; HYDROCHLOROTHIAZIDE; IRBESARTAN; ISRADIPINE; METOPROLOL; POTASSIUM ION;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BONE PAIN; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; MYALGIA; PRIORITY JOURNAL; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CONTROLLED CLINICAL TRIALS; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SAFETY; TETRAZOLES;

EID: 0031427249     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Murray CJL, Lopez AD: Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996, 274:740-743.
2. Dustan HP, Rocella EJ, Garrison HH:Controlling hypertension. A research success story. Arch Intern Med 1996, 156:1926-1935.
3. US Department of Health: Health United States. Hyattsville, Maryland: US Department of Health and Human Services publication (PHS) 96-1232.
4. Johnston GD: Dose-response relationships with antihypertensive drugs. Pharmacol Ther 1992,55:53-93.
5. Frick MH, McGibney D, Tyler HM: A dose-response study of amlodipine in mild to moderate hypertension. J Intern Med 1989, 225:101-105.
6. Frick MH, McGibney D, Tyler HM and Coinvestigators: Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. J Cardiovasc Pharmacol 1989, 12 (suppl 7):S76-S78.
7. Hamilton DV, Barnes PC, Bowles RML, et al.: Monotherapy with felodipine, a new calcium antagonist, in mild to moderate hypertension. J Cardiovasc Pharmacol 1987, 10 (suppl 10) :S111-S113.
8. Sluiter HE: Felodipine In hypertensive patients. A dose finding study In patients refractory to β-blocker monotherapy. Drugs 1987, 34 (suppl 3):97-106.
9. Simonsen K: Dose-response relationship and incidence of adverse reactions with isradipine in patients with essential hypertension. Am J Med 1989,86 (suppl 4A):91-93.
10. Martin A, Browning RC: Metoprolol in the aged hypertensive: a comparison of two dosage schedules. Postgrad Med J 1985, 61:225-227
11. Nader PC, Thompson JR, Alpem RJ: Complications of diuretic use. Semin Nephrol 1988,8:365-387.
12. Kaplan NM. Hypertension and diabetes. In Ellenberg and Rifkin's Diabetes Mellitus: Theory and Practice, chap 49,5th edn. Edited by Porte D, Shetwin RS. Stamford, Connecticut: Appleton and Lange; 1997.
13. Berglund G, Andersson O:Low doses of hydrochlorothiazide in hypertension. Antihypertensive and metabolic effects. Eur J Clin Pharmacol 1976, 10:177-182.